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The purpose of this paper is to present additional data concerning the mech- 
anism involved in the development,  in a  strain of influenza  virus, of lessened 
susceptibility  to  the  growth-inhibiting  effects of an  "immune"  environment. 
Data were presented in a previous report (1) concerning the passage of virus 
in mice vaccinated with the homologous and  with  closely related  strains.  The 
passage  strain  developed  the  capacity  to  multiply  more  freely  in  the 
"immunized" animals; the developed capacity was retained following frequent 
sub-passages--indicating  that  the  change  was  of an  hereditary  nature.  The 
"mutant"  strain  differed  from  the  parent  in  dominant  antibody-evoking 
antigen; however, analysis of the data from the dual aspects of antigenicity-- 
antibody-evoking capacity and  reactivity with  homologous and  heterologous 
antiserums--suggested  that  the  change  involved  quantitative  redistribution 
and  spatial  rearrangement  of existing  antigen  complexes.  Those  findings  are 
enhanced  and  extended  by  the  present  data. 
Materials  and Methods 
Strains of Virus.--Varlant-1 (MV2-M12-M2-M7)  (1)  was used as starting material  for 
the presently reported passage series. It was derived during passage of A/Berkeley-I/53 strain 
of influenza virus in mice which had been vaccinated  with formalinized, partially  purified, 
homologous, and closely related  strains  of virus:  10 passages were in mice vaccinated  with 
the parent  (A/Berkeley-I/53)  strain,  4 were in mice vaccinated  with both the parent and 
A/England-i/51 strains, and 9 were in mice vaccinated with the parent (A/Berkeley-I/53), 
A/England-I/S1, and A/England-I/54 strains. The A/Berkeley-I/53 strain  (isolated by Dr. 
E. H. Lennette)  had been selected because at the start of those previous experiments, it was 
one of the most recently  isolated strains  available.  It had not been passaged previously in 
this laboratory,  and had been through only 3 amniotic and 6 allantoic passages in Dr. Len- 
nette's laboratory.  Such a strain suited  the experimental  design in that it seemed to offer 
the chance of obtaining  dominant  antigens which had not been dominant  in known strains, 
---a condition which would free the experiments from the suspicion that resulting  variants 
may have been due to laboratory contamination. 
* This  investigation  was under the sponsorship of The Commission on Influenza of the 
Armed Forces Epidcmiological Board, and was supported,  in part, by the Office of the Sur- 
geon General, Department of the Army. 
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The starting material (Variant-l) was derived from a single egg infectious unit of mouse 
passage virus. During early passage in the vaccinated mouse series, it had been necessary to 
resort to allantoic fluid in order to continue the series. The fluid selected was from the virus 
titration of the mouse lung suspension of the previous passage. In that titration virus was 
detected in allantoic fluid of only one of five eggs inoculated with the 10  -5 dilution of the 10 
per cent mouse lung suspension and in none of the fluids of eggs inoculated with the 10  -6 
dilution. The fluid from that single embryonate egg with apparent infection was used for 
passage, 
Place and date of isolation of each of the thirty-two strains of virus used in the experiments 
are indicated by the strain designation in the text and tables. In  those instances in which 
strain designations have not followed the procedure suggested by the World Health Organiza- 
tion, the designation which had been assigned by the respective worker is indicated along with 
place and date of isolation. All stock strains had been dried under vacuum, while frozen, and 
then stored at 4°C. Antibiotics or other antimicrobial agents were not used in passage of the 
stock material; bacterial contamination of any kind is viewed as evidence of inadequacy of 
virus technical procedures. 
Vaccines.--Vaccines  were partially  purified virus suspensions which contained one part 
formalin in 5000. Allantoic fluids from embryonate eggs,  12  to  14 days old, which had been 
inoculated amniotically 2 or 3 days previously, were clarified  in an angle centrifuge at 4000 
m,~ for 30 minutes; the virus then was sedimentated in a  Spinco centrifuge at 40,000  I~.~M 
for 60 minutes, resuspended to one-fifth or one-tenth of the original volume in pH 7.2, M/15 
phosphate buffer or in distilled water, and again clarified  by centrifugation at 4000 m'M for 
30 minutes. Formalin was then added. Mter 2 hours at 37°C and 24 hours or 48 hours in the 
refrigerator (4°C),  the formalinized suspensions were tested for egg infectivity. None of the 
preparations contained detected egg infectious material. 
Antiserums.--Antiserums were obtained from rabbits which had been given three inocula- 
tions, each of either 5 or 2.5 ml of the respective vaccine at weekly intervals. The animals 
were bled 1 week after the third inoculation, and 3 weeks after the first; in general, inoculations 
were intravenous, but in some series they were intraperitoneal. The antiserums were obtained 
aseptically, inactivated at 56°C for 30 minutes, and then stored at 4°C without a preservative. 
The hemagglutination-inhibitory substances normally present in  serums were removed, 
as indicated in the text, either by treatment with cholera filtrate (2) or by pepsin digestion 
followed by fractional separation of the globulins, by slight modification of the method re- 
ported by Glaubiger for the partial purification of diphtheria and tetanus antitoxins (3). 
Vaccination  and  Passage.--Mice were vaccinated by intraperitoneal inoculation of 0.25 
ml quantities of vaccine. Intranasal inoculations were made while the mice were under ether 
anesthesia; the inocuhim, per mouse, was usually in excess of 0.1 ml. Because of the time re- 
quired for vaccination, mice were from 15 to 20 gm in weight when given the passage material 
intranasally. 
The initial inoculum was allantoic fluid from eggs which had been infected with Variant-1 
(MV2-M12-M2-MT) (1). In all but six instances subinoculations were made with suspensions 
of lungs from the 2 or 3 mice of the previous passage; the suspensions were approximately 10 
per cent by weight and were prepared by grinding the lungs in sterile distilled water with 
alundum as an abrasive. An aliquot of each suspension was tested for virus content by egg 
infectivity tests. In six instances, indicated in Table I, passage was made with allantoic fluids 
from eggs which had been used for the egg infectivity tests of the preceding successful mouse 
passage material. 
Egg  Infectivity  Tests.--In  order to  eliminate the hazards of contamination of the work 
areas, eggs were prepared before inoculation. The day preceding the test the shell and shell 
membrane were removed from the "butt" end of embryonate eggs, 10 or 11 days old; the open T. P. MAGILL 
TABLE I 
Vaccination and Passage Data 
443 
Mouse 
serial 
passage 
6 
7 
8 
9 
10 
11 
12 
Vaccination  Passage 
Strain of virus 
Albany-9/51 
N.Y.-I/53 
Stockholm-i/54 
Ist same 
2nd Albany-9/51 
N. Y.-I/53 
1st same 
Material  inoculated 
AUantoic fluid 
Variant-i (MV2- 
MI2-M2-M7) 
M-1 
M-2 
2nd 
0 
0 
England-I/51 
Berkeley-I/53 
AUantoic fluid 
M-2 
M2-NM1 
M2-NM2 
Same 
cc 
¢¢ 
Albany-9/51 
N. Y.-I/53 
1st same 
2nd  " 
1st  " 
2nd  " 
1st  " 
2nd  " 
1st  " 
M2-NM2-MI 
M2-NM2-M2 
M2-NM2-M3 
M2-NM2-M4 
M2-NM2-M5 
M2-NM2-M6 
M2-NM2-M7 
M2-NM2-M8 
M2-NM2-M9 
Passage 
summary 
M-1 
M-2 
M2-NM1 
M2-NM2 
M2-NM2-M1 
M2-NM2-M2 
M2-NM2-M3 
M2-NM2-M4 
M2-NM2-M5 
M2-NM2-M6 
M2-NM2-M7 
M2-NM2-M8 
M2-NM2-M9 
M2-NM2- 
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TABLE  I--Continued 
Mouse 
serial 
passage 
13 
14 
15 
16 
Vaccination 
Strain of vires 
2nd  " 
1st  " 
2nd  " 
Albany-9/51 
N. Y.-1/53 
Berkeley-I/53 
Variant-la 
1st same 
2nd  " 
Passage 
Day of 
Days  Egg  death  Lu~ 
after  Material inoculated  infec-  after  vacci-  lesioi s 
nation  tivity  inocu- 
lation 
log 
1st  "  11 
2nd  "  4 
5  England-  1/51 
Berkeley-I/53 
17  Same 
18  1st same 
2nd  " 
19  1st same 
2nd  " 
14  Allantoic fluid  7.9  3 
9  M2-NM2-M8 
10 
12 
2 
7  M2-NM2-M8-  5.1  2 
M1 
9  M2-NM2-M8-  5.7 
2  M2 
14 
4 
Passage 
summary 
d, 3, 3  M2-NM2- 
M8-M1 
0, 0, 1  M2-NM2- 
M8-M2 
M2-NM2-M8- 
M3 
Allantoic fluid 
M2-NM2-M8- 
M3 
M2-NM2-M8- 
M3-M1 
M2-NM2-M8- 
M3-M2 
Allantoic fluid 
M2-NM2-M8- 
M3-M2 
M2-NM2-M8- 
M3-M2-M1 
6.0 
7.9 
7.6 
5.1 
9.0 
6.9 
2  0, 0, 0  M2-NM2- 
MS-M3 
3  2, 2 
2  2, 3, 3  M2-NM2- 
4  M8-M3- 
M1 
3  2, 2, 2  M2-NM2- 
MS-M3- 
M2 
2  0, 0, 0 
2  1, 2  M2-NM2- 
M8-M3- 
M2-M1 
3  1, 1, 1  M2-NM2- 
M8-M3- 
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TABLE  I--Continued 
Va  ccina  tion  Passage 
Mouse 
serial 
passage ! 
20 
Strain  of virus 
Day of  Days  after  Egg  death  Lun~ 
vacci-  Material inoculated  infec-  after  lesiot  s 
nation  tivity  inocu- 
lation 
/og 
1st  Berkeley-I/S3 
2nd England-I/51  M2-NM2-M8-  4.7  2 
Berkeley-I/53  2  M3-M2-M2 
21  1st same 
2nd  " 
22  1st same 
2nd  " 
23  1st  same 
2nd  " 
24 
25 
26 
27 
11  M2-NM2-M8-  6.8  2 
4  M3-M2-M3 
13  M2-NM2-M8-  6.8  3 
6  M3-M2-M4 
16  M2-NM2-M8-  4.8  2 
9  M3-M2-M5 
2  3rd  England-I/51 
Berkeley-i/53 
Variant-la 
1st same 
2rid  " 
3rd  " 
1st same 
2nd  " 
3rd  " 
1st same 
2nd  " 
3rd  " 
1st  England-I/51 
Berkeley-I/53 
Variant-la 
2nd Varlant-1 
Ist same 
2nd  " 
18  M2-NM2-M8- 
11  M3-M2-M6 
4 
7.0  2 
20  M2-NM2-M8-  7.0  3 
13  M3-M2-M7 
6 
23  M2-NM2-M8-  4.8  2 
16  M3-M2-M8 
9 
7  Allantoic fluid 
M2-NM2-M8-  8.8  3 
M3-M2-M8 
4 
I0  M2-NM2-MS- 
7  M3-M2-M8- 
M1 
6.0  2 
Passage 
summary 
O,  O,  0  M2-NM2- 
M8-M3- 
M2-M3 
0, 0, 0  M2-NM2- 
M8-M3- 
M2-M4 
0, 0  M2-NM2- 
MS-M3- 
M2-M5 
I, 2  M2-NM2- 
M8-M3- 
M2-M6 
0,  I  M2-NM2- 
M8-M3- 
M2-M7 
0, 0  M2-NM2- 
M8-M3- 
M2-M8 
0, 0 
M2-NM2- 
4, 4, 4  M8-M3- 
M2-MS- 
M1 
0, 0  M2-NM2- 
M8-M3- 
M2-M8- 
M2  ('Carl, 
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end of the egg was covered with a glass staining dish, and the eggs incubated. The following 
morning, eggs containing embryos which had not survived the manipulation were discarded. 
Titrations were made in tenfold steps, each dilution being tested in six to eight eggs. All 
inoculations,  each of 0.25 ml, were made with  1~ inch,  23-gauge needles  directly into the 
amniotic fluid.  In order to reduce  possible  bacterial contamination from  the mouse lungs, 
the culture broth used to make the dilutions contained sufficient penicillin and streptomycin 
to provide for 250 units and 0.025 mg respectively, per each 0.25 ml inoculum. 
Hemagglutination-Inhibition  Tests.--The  test  mixtures  consisted  of  0.2  ml  volumes  of 
antiserum, virus suspension,  and 1/~ per cent suspension  of  chicken  erythrocytes. Mter  1 
hour at room temperature, hemagglutination was  read as complete (++),  partial (+), or 
negative (0), on the basis of pattern. 
Egg Protection  Tests.--Eggs  were prepared as described  above (egg infecti'dty  tests)  and 
then inoculated amniotically with 0.25 ml of a mixture of equal volumes of serum and virus 
suspension.  The mixtures contained from 108 to  104 egg infectious  units and were kept at 
37°C, in a water bath, for one-half hour before inoculation.  Virus suspensions were prepared 
from stock passage material by dilution with trypticase-soy culture broth, containing per 
inoculum 250 units of penicillin and 0.025 mg of streptomycin. Mter 3 days' incubation, the 
respective allantoic fluids were tested for hemagglutinating activity. The antibody titers were 
determined by the 50 per cent end-point method of Reed and Muench  (4). 
EX PERIMENTAL 
The plan of the experiment was  to  continue passage of the previously re- 
ported (1) variant strain in mice vaccinated with homologous and with closely 
related strains in an effort to produce strains which differed from known strains 
of influenza virus in a manner more marked than variant-1. The intent was to 
propagate the virus by mouse  to mouse passage but difficulties were encoun- 
tered when  the  strains included in  the vaccines were  changed,  which  neces- 
sitated resorting to allantoic fluid in six instances. Tests made during the course 
of  the  experiments  failed  to  disclose  the  anticipated  changes,  and  after  27 
passages in vaccinated mice,  the  series was  discontinued.  Subsequently,  fol- 
lowing more extensive analysis, it was found  that  the passage strain had ac- 
quired the capacity to evoke antibodies reactive with older known strains, while 
retaining the  capacity to  evoke antibodies against recent  strains.  Data  con- 
cerning vaccination and passage are summarized in Table I. 
Lessened susceptibility to  the deleterious effects of the  "immune"  environ- 
ment may develop to a relatively  high degree during passage in vaccinated mice. 
In the case of passages 23  (Table I) the mice had been vaccinated 16,  9,  and  2 
days previously with the single (Berkeley-i/53), the double (England-I/51 and 
Berkeley-I/53), and  the triple (England-I/M,  Berkeley-I/53,  and  Variant-l) 
vaccines,  respectively.  The  passage  inoculum  contained  1@ "s  units  of  virus 
per ml. When the mice were killed 48 hours later the lungs containedl07.° egg 
infectious units per ml. 
In general, whenever the infection was permitted to persist for 3  days the 
virus titer of the lungs tended to be lower than in those instances in which the 
infection was terminated in 48 hours.  The fall in titer was especially marked T. 1,. U.AC,  ILI,  447 
in those instances in which the mice were "hyperimmunized." For instance, the 
mice of passage 25 were of approximately the same vaccination status as mice 
of the preceding  (24)  passage, and the titers of the  two inoculums  were the 
same  (107);  however,  the  virus  titer  of the  lungs  in  the  former instance,  in 
which  the  infection was terminated  after 48  hours,  was  10~; whereas,  in  the 
latter instance,  in which  infection persisted for 72  hours,  the  titer decreased 
to 1@ .8  . 
Another  point  which may be significant is that  change of vaccine strains, 
even though closely related to the previous vaccine strains,  rendered passage 
more hazardous.  For example, the  starting  strain  (Variant-l)  had developed 
the capacity to multiply in mice which had been vaccinated with England-i/51, 
Berkeley-I/53, and England-i/54  strains (1). However, attempts were unsuc- 
cessful to passage Variant-1 in mice vaccinated with the related strains Albany- 
9/51,  New York-I/53,  and  Stockholm-I/54  (passages  1 and  2, Table I). 
Characterization of Strains on the Bases of Antibody-Evoking Capacity  and of 
Surface Reactivity.--It  was pointed out in an early study  (5)  that  strains of 
influenza virus possess two kinds of antigenic characteristics--the capacity to 
evoke antibodies on the one hand, and the relative reactivity with homologous 
and heterologousantiserums, on the other. The former characteristic was referred 
to as antigenicity  and the latter--because protection tests were used,  and for 
want of a better term--as aggressiveness. The one may be viewed as a measure- 
ment of the sum of the antigens included in and on the entire virus particle, 
capable of evoking detectable antibodies in a given animal,  whereas  the  other 
may be viewed as a  measurement of the reactivity of the antigens  which are 
present on the actual exposed surface of the particle, or sufficiently close to the 
surface to be within the sphere of attraction. Those two antigenic characteristics 
were determined for the parent (Berkeley-I/53) strain and for the two deriva- 
tives of that strain. 
t]emagglutination-Inhibition  Tests with Serums Treated with Cholera-filtrate.- 
The parent and two of the derived strains were compared with one another and with twenty- 
nine other strains. Antiserums were treated  with cholera filtrate to remove the normal in- 
hibitory substances, and then tested in constant dilution for capacity to inhibit hemagglutina- 
tion by serial threefold dilutions of the virus suspensions. The test mixtures contained equal 
volumes (0.2 ml) of the 1:25 dilution of cholera filtrate-treated  antiserum, virus suspension, 
and ~  per cent suspension of chicken erythrocytes. 
The data from those tests indicated that during passage in vaccinated mice 
the passage strain lost the broad surface reactivity of the parent  strain and 
developed a broader antibody-evoking capacity, and were interpreted to mean 
that a  rearrangement of the structure of the virus particle had occurred. The 
findings  seemed  to  have depended  upon  specific antigen-antibody reactions; 
treatment of the antiserums with cholera filtrate seemed to have been effective 448  SPATIAL REARRANGEMENT OF VIRUS 
in removing the  normal  inhibitory substances  because  tests  with  strains  of 
influenza B  virus  in  no instance showed inhibition of more  than 3  hemag- 
glutinating units. Nevertheless, in view of the implication of the data, it seemed 
desirable to retest antiserums from which the normal inhibitory substances had 
been removed by another procedure. 
Hemagglutination-Inhibition  Tests with Pepsin-Digested and Partially  Puri~ed 
A ntiserums.-- 
In addition to the procedure used  to remove the non-specific inhibitory substances, the 
tests with the pepsin-digested antiserums differed in two other aspects from the previous tests. 
Serial twofold dilutions of reconstituted antiserum globulin were tested against a  constant 
quantity (not less than 4, nor more than 8 hemagglutinating units) of virus. Also, the pepsin- 
digested and partially purified material  was from 4)ools of two  or  three antiserums which 
had been prepared at the same time and in the same manner. In the previous tests individual 
antiserums had been selected, because of high homologous titer, from those same groups of 
two or three which subsequently were pooled for pepsin digestion. 
RESULTS 
Pertinent data concerning the tests with cholera filtrate-treated serums are 
summarized ;~  Table II. The thirty-two strain designations listed in the left 
hand column (Table II) refer either to antiserums evoked by those strains, or 
to the virus suspensions. When the designation refers to antiserum, the respec- 
tive antiserum was used in tests with suspensions of the three strains of virus 
indicated by the headings of the three double columns to the right. Whenever 
the designations in the left hand column refer to suspensions of the respective 
virus, the suspensions were tested with antiserums evoked by the strains listed 
in the three double columns to the right. Thus, for each of the three compared 
strains  (Berkeley-I/53, Variant-l, and Variant-2)  the left hand data in each 
double column (under the heading Virus)  refer to surface reactivity with the 
inhibitory substances in the thirty-two antiserums. The right hand data in each 
of the three double columns (under the heading Antiserum)  refer to the capacity 
of the antiserum, evoked by that strain,  to inhibit hemagglutination by the 
thirty-two strains of virus. Because the hemagglutination-inhibition  tests were 
made with a  contant dilution of serum and serial threefold dilutions of virus 
suspension,  the results have  been  expressed  exponentially to  the  base  3,  in 
terms of hemagglutinating units of virus inhibited; that is, each numeral in the 
six columns of data indicates the number of tubes in the series  of threefold 
dilutions of virus in which hemagglutination was completely inhibited.  The 
various virus suspensions contained approximately the same number  (3 ~ to 3 6) 
of hemagglutinating units of virus. 
Surface Reactivity of the Berkeley-I~53 Strain.--The virus suspensions of the 
parent  strain,  Berkeley-I/53, reacted with a  broad  spectrum  of antiserums 
(Table II). Among the strains isolated in 1940 or earlier, significant reactivity No. 
TABLE II 
Comparison  of the Two Derived Strains with the Parent Strain (Berkdey-1/53) with Respect to 
Antibody-Evoking  Ca ,acity and to Surface Reactivity 
Inhibition* of hemagglutination 
Variant-2 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
Antibody~ rs ........................ 
Virus rs  ............ 
Swine-15/30 
EngL-W.S./33 
PR-8/34 
Phila./35 
Alaska/35 
N. Y.-Henry/36 
N. Y.-Patnode/36 
Aust.-Reid/39 
N. Y.-Coyle/40 
N. Y.-Niel./40 
Aust.-Bel./42 
Mass.-Beard/43 
Ft. C.-Weiss/43 
I-Iir  st 982/43 
FM1/46 
PR-Coamo/48 
St. John 2/49 
Sweden 3/50 
Brooklyn-M/50 
F.Warren/50 
England-I/51 
Albany-9/51 
India-Nich./52 
Chile-i/53 
N. Y.-1/53 
Berkeley-I/53 
Variant-1 
Vafiant-2 
England-I/54 
PR-301/54 
England-19/55 
Albany-I/55 
Virus 
Anti- 
serum 
0 
Berkel.-1/53 
Virus  Virus 
Anti- 
seruin 
0  1  0 
0  0  0 
2  0  0 
2  0  1 
0  0  0 
2  0  1 
1  0  0 
2  0  1 
1  0  0 
2  0  1 
1  0  0 
1  0  1 
2  1  1 
1  0  0 
1  2  1 
2  1  3 
4  0  3 
5  3  5 
3  0  1 
3  1  1 
5  2  4 
4  3  3 
1  3  0 
5  3  5 
5  3  5 
5  5  4 
5  4  5 
5  4  5 
4  4  3 
4  4  5 
4  2  3 
4  3  5 
Variant-1 
Anti- 
seruln 
1 
0  0 
0  0 
0  1 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
2  1 
1  0 
4  1 
4  5 
0  3 
2  3 
0  1 
1  0 
3  2 
3  4 
1  0 
2  3 
4  5 
5  4 
5  5 
5  5 
4  2 
4  4 
1  4 
3  3 
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* The  results  are  expressed  exponentially  to  the  base  3  in terms of threefold units of 
hemagglutinin inhibited by  the  1/25  dilution  of  respective  serum. 
The listings in the first column refer to antiserum  whenever reference is made to data 
included in columns to the fight which are headed Virus. They refer to ~/rus whenever refer- 
ence is made to data included in the columns headed Antiserum. 450  SPATIAL REARRANGEMENT  OF VIRUS 
(inhibition of 9  hemagglutinating units of virus)  was  evident in tests  with 
antiserums evoked by PR-8/34 (No. 3), Philadelphia/35 (No. 4), New York- 
Henry/36  (No.  6),  Australia-Reid/39  (No.  8),  and  New  ¥ork-Nielson/40 
(No. 10) strains. Also, surface reactivity was marked with antiserums evoked 
by most strains isolated after 1945. 
Antibody-Evoking  Capacity  of  the  Berkeley-i~53  Straiu.--The  antibody- 
evoking capacity was more limited. Antibodies evoked by the Berkeley-i/53 
vaccines did not include those specific for older strains in quantities detectable 
by the methods employed, except for the suggestive inhibition of 3  hemag- 
glutinating units in the case of swine. That is, whereas the respective antigens 
seem to have covered an area of the surface of the Berkeley-I/53 virus particle 
sufficiently  extensive to be detected by antibodies evoked by those five pre-1941 
strains  (PR-8/34,  Philadelphia/35,  New  York-Henry/36,  Australia-Reid/39, 
and New York-Nielson/40), those antigens seem to have been quantitatively 
insufficient to evoke detected antibodies reactive with virus suspensions of those 
same pre-1941  strains. 
Surface Reactivity of the Derived Strains.--Virus suspensions of both of the 
derived strains reacted with fewer of the thirty-two antiserums than did the 
parent strain (Berkeley-i/53). Accordingly, if the assumption is correct that 
the  inhibition of hemagglutination in  those tests  was a  measure of specific 
surface antigen, the antigen complexes for which test antibodies were available 
were more limited on the surface of the derived strains than on the surface of 
Berkeley-i/53. None of the antigen complexes specific  for antibodies evoked 
by the fifteen pre-1948  strains were present in significant quantities (exponents 
greater than 1, Table II) on the surface of either variant; moreover, there is a 
suggestion that the loss may have been progressive in that there were fewer 
instances of suggested inhibition (exponent 1) in the case of Variant-2 than in 
the  case  of  Variant-1. 
Antibody-Evoking Antigens of the Derived Strains.--Antigens which were not 
evident in either Variant-1 or Variant-2 virus in tests with antiserums to the 
fifteen pre-1948  strains were nevertheless present in sufficient quantities in the 
virus suspensions to evoke antibodies which reacted with suspensions of pre- 
1948  strains  of virus.  As measured by reactivity with the  FM-1  antiserum 
(No.  15),  significant quantities of FM-1  antigen were not detected in either 
variant. However, vaccination with the variant suspensions evoked relatively 
high titers of FM-1 antibodies; the 1:25 dilution of antiserum in each instance 
inhibited 81 (3*) hemagglutinating units of FM-1 virus. In tests with Weiss/43 
(No. 13), a  similar relationship occurred but was more marked in the case of 
Variant-2.  In  the  tests  with  F.  Warren/50  (No.  20),  Hirst  982/43  (No. 
14),  Massachusetts-Beard/43  (No.  12)  and New York-Nielson/40  (No.  10), 
significant antibody-evoking antigens in  the  absence  of  significant surface- 
reacting antigens were evident in the case of Variant-2 but not Variant-1. T,  P. MAGILL  451 
Results of Tests with Pepsin-Digested  Antiserums.--Data concerning  the tests 
with  pepsin-digested  and  partially  purified  antiserums  are  summarized  in 
Table in, the arrangement of which is the same as that of Table II. However, 
because serial twofold dilutions of the reconstituted serums were tested with a 
constant quantity of virus the results are presented exponentially in terms of 
the greatest twofold initial  dilution of antiserum  which completely inhibited 
the hemagglutinating activity of the test aliquot of virus. 
An obvious discrepancy between the results with the cholera filtrate-treated 
serums (Table II) and those with the pepsin-digested serums (Table III) con- 
cerns the surface reactivity of Berkeley-I/53. The former (Table II) suggest a 
broad range of antigens, reactive with antibodies evoked by some of the oldest 
known strains; the latter (Table III) indicate that the surface reactivity with 
serums evoked by pre-1941 strains was no broader in the case of Berkeley-I/53 
than in the case of the two derived strains. Although the possibility exists that 
the discrepancy depends upon the more effective removal of inhibitory sub- 
stances by pepsin digestion,  it probably depends in part upon loss of antibody 
because of the drastic treatment. 
A  discrepancy  of  a  somewhat  different  kind  occurred  in  tests  with 
Massachusetts-Beard/43.  In  tests  with  the  cholera  filtrate-treated  serums 
(No.  12,  Table II)  no inhibition  was evident with Berkeley-I/53 antiserum, 
whereas the Variant-2 antiserum inhibited 27 units (38) of Beard hemagglutinin. 
However, in the tests of pepsin-digested antiserums  (No. 7, Table III), both 
Berkeley-I/53  and  Variant-2  antiserums  effected  significant  inhibition  of 
hemagglutination.  It  is  noteworthy  that  in  neither  test  did  the  Variant-1 
antiserum  effect significant  inhibition. 
From  the viewpoint of broadening  of the antibody-evoking capacity,  the 
data  (Table III)  agree well with those of the tests summarized in Table II. 
The broadening of the antibody-evoking capacity to include antibodies reactive 
with the early strains is evident in the case of New York-Nielson/40 (No. 6, 
Table III; No. 10, Table II) and Fort. C.-Weiss/43 (No. 8, Table III, No. 13, 
Table II). In the tests with pepsin-digested antiserums, the broadening seems 
also to include England-W.S./33  (No.  1, Table III).  At the same time,  the 
capacity to evoke antibodies for the more recently isolated strains seems not 
to have been impaired. 
It is of interest that  on the basis of the data in Table III,  the antibody- 
evoking capacity of Variant-1  is more limited than  that  of its parent strain 
(Berkeley-I/53). The seeming decrease in apparent antigenic relationship is in 
accord with  the original,  more restricted analysis of Variant-1  (1);  that  is, 
there  seems  to  have  been a  continuation  of progression  in  replacement  of 
dominant  antigens.  The  differences  between  antibody-evoking  capacity  of 
Variant-2 as compared with that of its antecedent Variant-1 are striking (Table 
III).  Variant-2  exhibited  significantly  greater  antibody-evoking  capacity No. 
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against  England-W.S./33,  New  York-Nielson/40,  Massachusetts-Beard/43, 
and Fort C.-Weiss/43 (Nos.  1, 6, 7, and 8, Table III). 
Demonstration,  by  Egg  Protection  Tests,  of  Decreased  Susceptibility  of  the 
Derived Strain to Action of Antibodies.--The lessened susceptibility of Variant-2 
as compared with the parent (Berkeley-I/53) strain to antibody activity, which 
was evident in the tests with cholera filtrate-treated antiserums (Table II), was 
TABLE III 
Hemagglutination Inhibition* Tests with the Globulin Fraction of Pepsin-Digested Antiserums 
Berkel.-1/53 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Antiserum~  vs  ...................... 
Virus vs  ............................ 
Engl.-W.S./33 
PR-8/34 
Phila./35 
N. Y.-Henry/36 
Aust .-Reid/39 
N. Y.-Niel./40 
Mass.-Beard/43 
Ft. C.-Weiss/43 
FM-1/46 
F.Warren/50 
Engl.-1/51 
Berkeley-I/53 
Variant-1 
Variant-2 
Engl.-1/54 
Virus 
Anti- 
serum 
452 
Variant-1 
Virus 
0 
0 
0 
0 
0 
0 
0 
2 
4 
3 
6 
9 
9 
8 
I0 
Variant-2 
Virus  I 
Anti-  0  Anti-  serum  serum 
0  2 
0  0 
0  0 
0  0  0 
0  0  0 
0  0  3 
1  0  4 
i  0  5 
4  0  5 
0  2  1 
4  4  5 
6  7  5 
9  7  8 
7  7  7 
6  9  5 
* Inhibition of hemagglutination  is expressed exponentially  to  the base 2, in terms  of 
twofold dilutions of respective antiserum which inhibited the hemagglutinating effect of the 
fixed amount of virus (4 to 8 units). 
The listings in the first column refer to antiserum whenever reference is made to data 
included in columns to the right which are headed Virus. They refer to virus whenever refer- 
ence is made to data included in the columns headed Antiserum. 
evident also in egg protection tests,  results of  which  are  summarized in Ta- 
ble  IV. 
In order to be reasonably assured of their purity, the test virus suspensions were derived 
from three serial passages with single egg infectious units. The test antiserums were untreated 
and included five which had been used in the previous tests, and two pairs (W.S. and PR8) 
which had been recently prepared. Because the antiserums were tested in twofold dilutions, 
the results  (Table IV)  are presented  exponentially to the base 2, in terms  of 50 per cent 
infectivity. 
The  antiserums evoked  by  the  pre-1944  strains of  virus were  even more 
effective in preventing  infection  of embryonate eggs (Table IV) by the Berkeley- T.P.M.AGILL  453 
1/53 than in inhibiting  hemagglutirmtion (Table II) by that strain. Antiserums 
evoked by all seven of the test strains effected significant protection against 
infection by the Berkdey-1/53 strain, whereas  the same antiserums exerted 
relatively little egg protective capacity versus the derived Variant-2. 
Specificity of the Berkeley-I~53 Surface Antigens for Antibody Evoked by the 
Swine Strain of Virus.--In order to obtain additional assurance of the specificity 
of the reactions in the foregoing tests, aliquots of the pooled swine virus anti- 
serums (R55-22 and R55-23, Table IV), were adsorbed with partially purified 
Berkeley-I/53 strain of virus and then tested for capacity to prevent infection 
of embryonate eggs by that strain. The virus previously had been through 3 
TABLE IV 
Effectiveness  of A ntibodies Evoked by Pre-1944 Strains in Egg Protection Tests  with  Berkdey-1/53 
and Variant-g Strains 
Antiserum 
Swine R55-22 and R55-23 
W.S. R60-26 
W.S. R60-27 
PR8 R60-59 
PR8 R60-63 
Phila./35  R55-16 
Aust.-Reid/39 R55-47 
N. Y.-Nielson/40 R55-21 
Mass.-Beard/43 R55-49 
Virus 
Berkeley-l/f3  Variant-2 
2.9*  1.2 
2.8  <1. 
2.8  0 
2.9  0 
>3.0  0 
1.8  0 
1.9  0 
1.8  1.6 
3.0  <1. 
* Expressed exponentially to the base 2, in terms of the 50 per cent end-point of infec- 
tivity. 
serial passages  with  single egg  infectious units--a reasonable assurance that 
the passage material contained but a  single strain. 
Allantoic fluid was clarified in an angle centrifuge at 4000 m~M for 30 minutes; the virus 
then was sedimentated in a Spinco centrifuge at 40,000 m,M for an hour, suspended in distilled 
water to ~oth its original volume, and again centrifuged at 4000 m,~ for  one-half an hour. 
Two S.0 ml aliquots of the concentrated virus suspension were centrifuged at 40,000 m,g for 
an hour, and sediment from one was suspended in a 2.5 ml aliquot of the swine virus antiserum. 
After overnight  refrigeration (4°C), the serum-virus mixture  and, also, an untreated 2.5 ml 
aliquot of the antiserum were mixed with a sufficient quantity of packed chicken erythrocytes 
to provide a S per cent suspension. After 20 minutes at 0°C, the erythrocytes  were removed 
by centrifugation. The adsorbed aliquot of antiserum then was absorbed a second time in the 
same manner. Both specimens of antiserum, then, were adsorbed twice with chicken erythro- 
cytes. In order to inactivate any virus which had not been  removed by adsorption with chicken 
erythrocytes, the aliquots of antiserum were heated at 56*(:: for 60 minutes. Equal volumes of 
serial twofold dilutions of the two aliquots of antiserum were mixed with a l/S00 dilution of 
Berkeley-I/S3 allantoic fluid, which provided 108.~ egg infectious units of virus per inoculum. 454  SPATIAL REARRANGEMENT OF VIRUS 
The 50 per cent egg protection titers of the two aliquots of antiserum were 
as  follows: 
Not adsorbed  1 : 12 
Adsorbed  0 
Control tests of the adsorbed aliquot of antiserum were made by inoculating 
eggs with the 1 : 2 dilution to which no additional virus had been added. None 
of the inoculated  eggs showed any evidence of infection,  indicating  that  the 
virus used for adsorption had been completely removed, or inactivated. 
DISCUSSION 
Both  the  previously reported  experiments  (1),  and  those  reported  in  the 
present paper were part of the same plan to test the idea that the influenza virus 
may have undergone changes under the impetus of biologic pressures exerted 
by the environment in which  the virus is naturally propagated--an environ- 
ment  provided  by  the  host  population  which  is  being  progressively 
"immunized" during the very process of virus propagation. It had been antici- 
pated, in keeping with the concept that the influenza virus had undergone a 
series of changes characterized by a progression of dominant antigen complexes 
(6-8),  that  the derived  strains  would  be characterized  by dominant  antigen 
complexes which had not been dominant in previously known strains. 
It was noted in early studies that the components which  were dominant in more 
recently isolated strains had not been dominant in earlier strains (9), but the basis for 
the differences was not clear at that time. It had been suspected that the virus was 
unstable and might be subject to change under the impetus of environmental pressures 
(10), but it remained for Hirst to first present experimental evidence of the unstable 
nature; he showed that passage in mice of a strain that previously had been passaged 
only in embryonate eggs might result in significant  antigenic change (11). Archetti 
and Horsfall showed  that changes develop when mixtures of virus and heterologous 
antiserum are passaged in embryonate eggs (12). Isaacs and Andrewes obtained anti- 
genic changes during passage in embryonate eggs of virus and homologous  antiserum 
(13); they considered  the changes,  however, to be an expression  of the P-Q-R varia- 
tion  of Van  der Veen  and Mulder  (14).  Subsequently,  Gerber, Loosli,  and  Hamre 
obtained antigenic changes during passage of the virus in mice which  had been vac- 
cinated with the homologous strain (15), and they showed that the "new" dominant 
antigen complex had been present during early passages as a minor component. Simi- 
lar findings,  that the dominant antigen of the derived strain had been present in the 
parent strain, were reported independently from this laboratory (1). 
The evidence  that antigen  complexes  which  were dominant in  the  older  known 
strains persist as less obvious components of more recent strains, is in keeping with the 
findings of Jensen and Francis; those workers tested representative strains by adsorp- 
tion techniques,  and concluded  "that no completely new  antigens have been found T. P.M.AGILL  455 
of late nor have the antigenic components of strains  isolated several years ago dis- 
appeared"  (16). 
With respect to Variant-l, the data presented in this report are in keeping 
with the previously reported results which indicated a progression in replace- 
ment of dominant antigen complexes (1); the data indicate a  contraction of 
range as measured by antigens which were dominant in the older known strains, 
both with respect to surface reactivity and to antibody-evoking capacity. Con- 
tinued passage  of Variant-1  in vaccinated mice, however, did not effect the 
anticipated  continued progression  of dominant antigens.  Instead,  the virus 
developed an increased capacity to evoke antibodies which reacted with the 
older known strains of virus; that is, antigen complexes which had been dom- 
inant in earlier strains regained prominence in the derived strain. 
It might be reasoned on the basis of present biologic  concepts that the re- 
currence of the previously dominant antigen complexes was a back-mutation, 
in a qualitative  sense; that is, antigens which had been lost through successive 
qualitative changes had been regained through a  series  of reverse qualitative 
changes. The present data, however, suggest that the antigens had not been 
lost, but had been present in the parent strain in minor amounts. 
The data indicate that during passage in the vaccinated mice an alteration 
occurred which involved an exchange of surface reactivity for antibody-evoking 
capacity; that is, there seems to have been a quantitative redistribution and a 
spatial rearrangement of the antigen complexes.  The parent,  Berkeley-I/53, 
strain  possesses  a  mosaic  of readily accessible  complexes which react  with 
antiserums evoked, not only by recent strains, but by the older known strains. 
The broad  surface reactivity seems  not to be  associated with a  mixture of 
strains because it persists after serial passage of single infectious units of the 
virus. Also, the data (especially those derived from egg protection tests) suggest 
that the surface reactivity depended upon specific antigen-antibody reactivity. 
The concept of a structure in which the virus surface is anfigenically distinct 
from inner virus bulk was proposed in one of the earliest studies of the problem 
(5);  Isaacs,  Depoux,  and  Fiset  (17)  suggested a  similar explanation for the 
P-Q-R variation of Van der Veen and Mulder (14);  and it seemed to  offer a 
plausible explanation of the data included in the previous report (1). 
The altered arrangement of the virus particle has persisted through numerous 
subpassages over a  period of 6 years. Accordingly, the change must be con- 
sidered to have been hereditary. And, in view of the concept that phenotypic 
expressions are controlled by individual hereditary units, the hereditary, quan- 
titative change in phenotype suggests a quantitative change in genotype. The 
data,  thus,  add  weight to  the  suggestion  (1)  that  influenza virus variation 
(i.e.,  ,'mutation")  may result  from a  rearrangement  of  existing hereditary 
elements, rather than from a qualitative change in one or more of the elements. 456  SPATIAL  REARRANGEMENT  OF  VIRUS 
SUMMARY 
During passage in mice which had been vaccinated with the homologous, 
and with closely related strains of influenza virus, the passage strain developed 
a  lessened susceptibility to the deleterious effects of the "immune" environ- 
ment, concomitant with which was a  developed capacity to evoke antibodies 
which reacted with earlier strains of virus--a capacity which was inapparent 
in the parent strain.  However, the parent strain exhibited a  relatively broad 
range of surface reactivity which was not apparent in the derived strain. 
The data are interpreted to mean that the hereditary change resulted from 
spatial rearrangement and quantitative redistribution of antigens in the virus 
particle (in which the surface is viewed as being distinct from the inner bulk), 
and  are  viewed  as  enhancing  the  idea  that  influenza  virus  variation  (i.e., 
"mutation") may result from a rearrangement of existing hereditary elements. 
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